Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Concomitant Treatment With Ruxolitinib And Deferasirox In The Management Of Iron Overload In Patients With Myelofibrosis: A Multicenter Italian Experience

Elena Maria Elli,Ambra Di Veroli,Alessandra Iurlo,Ida Carmosino,Giulia Benevolo,Elisabetta Abruzzese,Massimiliano Bonifacio,Emanuele Sutto,Nicola Polverelli,Marianna Caramella,Daniela Cilloni,Mario Tiribelli,Giovanni Caocci,Elena Crisa,Raffaele Porrini,Rossella Renso,Uros Markovic,Daniele Cattaneo,Lucia Biale,Michela Ansuinelli,Malgorzata Monika Trawinska,Luigi Scaffidi,Massimo Breccia,Carlo Gambacorti-Passerini,Giuseppe A. Palumbo,Roberto Latagliata

BLOOD（2019）

Cited 2|Views12
No score
Abstract
Introduction: Deferasirox (DFX) is the currently available iron-chelation therapy (ICT) for the management of iron overload (IOL), mainly in myelodysplastic syndromes; recently, two retrospective independent studies (Di Veroli, 2018; Elli, 2019) demonstrated that a treatment with DFX is feasible and effective also in the setting of myelofibrosis (MF). However, no data are still available regarding the concomitant use of DFX in patients (pts) treated with Ruxolitinib (Rux).
More
Translated text
Key words
Iron Overload,Ruxolitinib Therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined